Search results for "From ACP Journal Club"


 
Results 61 - 70 of about 133 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death

The review suggests that treating diabetes with strict glycemic control does not reduce mortality or cardiovascular risk or slow progression of kidney disease, and the results question whether strict glycemic control for preventing any complications is warranted, ACP Journal Club authors wrote.
https://diabetes.acponline.org/archives/2017/11/10/8.htm
10 Nov 2017

Self-monitoring of blood glucose did not improve HbA1c or QOL at 1 year in non-insulin-treated type 2 diabetes

The randomized controlled trial adds to the evidence about routine use of self-monitoring of blood glucose for all patients with type 2 diabetes, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2017/11/10/7.htm
10 Nov 2017

Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk

An ACP Journal Club commentary noted that the mechanism by which liraglutide improves renal outcomes is uncertain and that renal benefit was driven by a decrease in the surrogate outcome of macroalbuminuria, with measures of renal impairment remaining unchanged.
https://diabetes.acponline.org/archives/2018/01/12/9.htm
12 Jan 2018

Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes

While exenatide can be considered a second-line option for patients with type 2 diabetes and some may prefer its once-weekly dosing, those at high cardiovascular risk should receive agents with demonstrated cardiovascular benefit, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/01/12/10.htm
12 Jan 2018

Review compares effectiveness, cost, and safety of second-line drugs for diabetes

The review found that sulfonylureas were more cost-effective than newer agents, but an ACP Journal Club commentary stressed the importance of shared decision making in the choice of a second agent.
https://diabetes.acponline.org/archives/2018/02/09/6.htm
9 Feb 2018

Review: Adding a DPP-4 inhibitor to an SGLT-2 inhibitor reduces genital, but not genitourinary, tract infections

The authors of an accompanying ACP Journal Club commentary noted that although the risk for bias in the five reviewed studies was reportedly low, the results were imprecise and inconsistent, leaving little confidence in the evidence of an apparent reduction in infection risk with dipeptidyl peptidase-4 (DPP-4) inhibitors.
https://diabetes.acponline.org/archives/2018/04/13/7.htm
13 Apr 2018

Intensive weight management in primary care improved weight loss and remission of type 2 diabetes

The author of an ACP Journal Club commentary said that the intervention effect was strong enough to prompt a reconsideration of primary care management of obesity and that the results of the trial may motivate patients to lose enough weight to reverse diabetes.
https://diabetes.acponline.org/archives/2018/04/13/8.htm
13 Apr 2018

In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER

Exenatide is still an effective alternative for patients who cannot tolerate semaglutide due to gastrointestinal adverse events, noted the ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/05/11/7.htm
11 May 2018

In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events

The study provides compelling evidence for clinicians to recommend real-time continuous glucose monitoring to their patients at high risk for severe hypoglycemia, the ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2018/06/08/7.htm
8 Jun 2018

In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization

If the results are confirmed, sodium–glucose co-transporter-2 inhibitors will become a dominant strategy over standard glucose-lowering therapies for treating diabetic kidney disease, according to the ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/06/08/6.htm
8 Jun 2018

Result Page: Prev   2   3   4   5   6   7   8   9   10   11   Next